Interleukin 35: Critical regulator of immunity and lymphocyte-mediated diseases.
Bethesda, United States. In Cytokine Growth Factor Rev, Oct 2015
Although our current understanding of the immunobiology of IL-35 or its subunits (p35 and Ebi3) is still rudimentary, our goal in this review is to summarize what we know about this enigmatic cytokine and its potential clinical use, particularly in the treatment of CNS autoimmune diseases.
Interleukin-35: Expanding Its Job Profile.
Pittsburgh, United States. In J Interferon Cytokine Res, Jul 2015
Despite the early predictions for an immunomodulatory role for the Ebi3/p35 heterodimer in placental trophoblasts, IL-35 biology remained elusive until 2007 when it was established as a Treg-restricted inhibitory cytokine.
Interleukin-35 induces regulatory B cells that suppress autoimmune disease.
Bethesda, United States. In Nat Med, 2014
Treatment of mice with IL-35 conferred protection from experimental autoimmune uveitis (EAU), and mice lacking IL-35 (p35 knockout (KO) mice) or defective in IL-35 signaling (IL-12Rβ2 KO mice) produced less Breg cells endogenously or after treatment with IL-35 and developed severe uveitis.